Literature DB >> 22417909

Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.

Dominique Cadosch1, Sebastian Bonhoeffer, Roger Kouyos.   

Abstract

The adherence of patients to therapy is a crucial factor for successful HIV anti-retroviral therapy. Imperfect adherence may lead to treatment failure, which can cause the emergence of resistance within viral populations. We have developed a stochastic model that incorporates compartments of latently infected cells and virus genotypes with different susceptibilities to three simultaneously used drugs. With this model, we study the impact of several key parameters on the probability of treatment failure, i.e. insufficient viral suppression, and the emergence of resistance. Specifically, we consider the impact of drug dosage, drug half-lives, fitness costs for resistance, different basic reproductive numbers of the virus and the influence of pre-existing mutations under various levels of adherence. Furthermore, we also investigate the influence of different temporal distributions of non-adherent days (drug holidays) during a treatment. Factors that promote resistance evolution include a high reproductive number, extended drug holidays and poor adherence. Pre-existing mutations only have a substantial effect if they confer resistance against more than one drug. Overall, our study highlights the importance of the interactions between imperfect adherence, pharmacodynamics, pharmacokinetics and latently infected cells for our understanding of drug resistance and therapy failure in HIV anti-retroviral therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22417909      PMCID: PMC3405760          DOI: 10.1098/rsif.2012.0127

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  31 in total

Review 1.  Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.

Authors:  Roger J Pomerantz
Journal:  HIV Clin Trials       Date:  2003 Mar-Apr

2.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

Authors:  M A Nowak; A L Lloyd; G M Vasquez; T A Wiltrout; L M Wahl; N Bischofberger; J Williams; A Kinter; A S Fauci; V M Hirsch; J D Lifson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

4.  Dynamics of HIV infection of CD4+ T cells.

Authors:  A S Perelson; D E Kirschner; R De Boer
Journal:  Math Biosci       Date:  1993-03       Impact factor: 2.144

5.  Modeling plasma virus concentration during primary HIV infection.

Authors:  M A Stafford; L Corey; Y Cao; E S Daar; D D Ho; A S Perelson
Journal:  J Theor Biol       Date:  2000-04-07       Impact factor: 2.691

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy.

Authors:  Narendra M Dixit; Martin Markowitz; David D Ho; Alan S Perelson
Journal:  Antivir Ther       Date:  2004-04

8.  Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Authors:  Ajay K Sethi; David D Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant
Journal:  Clin Infect Dis       Date:  2003-09-19       Impact factor: 9.079

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

Authors:  Vivek Jain; Teri Liegler; Eric Vittinghoff; Wendy Hartogensis; Peter Bacchetti; Lauren Poole; Lisa Loeb; Christopher D Pilcher; Robert M Grant; Steven G Deeks; Frederick M Hecht
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

View more
  11 in total

1.  Association Between Self-Reported Adherence and HIV Viral Load Suppression Among Older Children and Adolescents.

Authors:  Chido Dziva Chikwari; Rashida A Ferrand; Victoria Simms
Journal:  J Acquir Immune Defic Syndr       Date:  2017-11-01       Impact factor: 3.731

2.  Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Authors:  Joshua T Schiffer; David A Swan; Amalia Magaret; Lawrence Corey; Anna Wald; Joachim Ossig; Helga Ruebsamen-Schaeff; Susanne Stoelben; Burkhard Timmler; Holger Zimmermann; Murad R Melhem; Scott A Van Wart; Christopher M Rubino; Alexander Birkmann
Journal:  Sci Transl Med       Date:  2016-02-03       Impact factor: 17.956

3.  Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.

Authors:  Alison F Feder; Kristin N Harper; Chanson J Brumme; Pleuni S Pennings
Journal:  Elife       Date:  2021-09-02       Impact factor: 8.140

4.  Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.

Authors:  Hongwei Zhang; Ronghua Jin; Cheng Yao; Tong Zhang; Meixia Wang; Wei Xia; Haiyan Peng; Xiaojuan Wang; Rongjian Lu; Changjin Wang; Dong Xie; Hao Wu
Journal:  AIDS Res Ther       Date:  2016-02-10       Impact factor: 2.250

5.  Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains.

Authors:  J M Kitayimbwa; J Y T Mugisha; R A Saenz
Journal:  Theor Popul Biol       Date:  2016-08-20       Impact factor: 1.570

6.  Health Literacy and Medication Adherence Among Patients Treated in a Free Health Clinic: A Pilot Study.

Authors:  Mark T Sawkin; Sara J Deppe; Joanie Thelen; Steven C Stoner; Craig A Dietz; Rafia S Rasu
Journal:  Health Serv Res Manag Epidemiol       Date:  2015-06-04

Review 7.  Insight into treatment of HIV infection from viral dynamics models.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Martin A Nowak; Robert F Siliciano
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

8.  Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study.

Authors:  Adino Tesfahun Tsegaye; Wagaye Alemu; Tadesse Awoke Ayele
Journal:  Pan Afr Med J       Date:  2019-06-06

9.  First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia.

Authors:  Mohammed Biset Ayalew; Dawit Kumilachew; Assefa Belay; Samson Getu; Derso Teju; Desalegn Endale; Yemisirach Tsegaye; Zebiba Wale
Journal:  HIV AIDS (Auckl)       Date:  2016-09-02

10.  Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals.

Authors:  Gavin C Sampey; Sergey Iordanskiy; Michelle L Pleet; Catherine DeMarino; Fabio Romerio; Renaud Mahieux; Fatah Kashanchi
Journal:  Viruses       Date:  2020-09-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.